Skip to main content
Jeffrey Meyerhardt, MD, Oncology, Boston, MA, Brigham and Women's Hospital

JeffreyAMeyerhardtMDMPH

Oncology Boston, MA

Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Dr. Meyerhardt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Meyerhardt's full profile

Already have an account?

Summary

  • Dr. Jeffrey Meyerhardt is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Yale University School of Medicine and has been in practice 20 years. He specializes in gastrointestinal oncology.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
  • Yale School of Medicine
    Yale School of MedicineClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1999 - 2024
  • RI State Medical License
    RI State Medical License 2020 - 2020
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Aspirin Use and Risk of Colorectal Cancer Among Older Adults  
    Long H Nguyen, Kimmie Ng, Jeffrey A Meyerhardt, Andrew T Chan, JAMA Oncology
  • Association of Diet Quality with Survival Among People with Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial  
    Kimmie Ng, Chloe Atreya, Howard S Hochster, James N Atkins, Richard M Goldberg, Charles D Blanke, Jeffrey A Meyerhardt, JAMA Network Open
  • Association of Coffee Intake with Survival in Patients with Advanced or Metastatic Colorectal Cancer  
    I-Wen Chang, Charles D Blanke, Alan P Venook, Richard M Goldberg, Jeffrey A Meyerhardt, Kimmie Ng, JAMA Oncology

Lectures

  • Lessons From IDEA: Duration in Stage II and III Colon Cancer 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Other

Authored Content

  • Vitamin D Status After Colorectal Cancer Diagnosis and Patient Survival According to Immune Response to TumourOctober 2018

Press Mentions

  • Do You Really Need That Colonoscopy?
    Do You Really Need That Colonoscopy?October 24th, 2022
  • Panitumumab Bests Bevacizumab in Metastatic Left-Sided Colon Cancer That Is RAS Wild-Type
    Panitumumab Bests Bevacizumab in Metastatic Left-Sided Colon Cancer That Is RAS Wild-TypeJune 5th, 2022
  • Sugary Drinks May Double Bowel Cancer Risk in Women Under 50
    Sugary Drinks May Double Bowel Cancer Risk in Women Under 50May 9th, 2021
  • Join now to see all

Grant Support

  • Exercise And Metformin To Impact Hyperinsulinemia In Colorectal Cancer SurvivorsNational Cancer Institute2011
  • The Influence Of Diet And Lifestyle On Patients With Advanced Colorectal CancerNational Cancer Institute2010–2011
  • The Role Of Pi3-Kinase Signaling Pathway In Defining Sensitivity And ResistanceNational Cancer Institute2007–2011
  • Predictors Of Outcome In Colorectal CancerNational Cancer Institute2003–2007

Hospital Affiliations